Twelve-Month Follow-Up and Economic Evaluation of an Alternative Care Provider Clinic for Severe Sleep-Disordered Breathing.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41587636.
- Also identified by DOI 10.1016/j.chest.2026.01.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Use of nonphysician alternative care providers (ACPs) can improve timely access to sleep-disordered breathing (SDB) care, and previous studies have demonstrated beneficial short-term clinical outcomes. Longer-term clinical and economic impacts of an ACP model for patients with severe SDB have not been evaluated. Is ACP-led care of SDB effective and cost-effective compared with standard care by a sleep physician? One-year follow-up data from a randomized controlled trial conducted among patients with severe SDB, randomized 1:1 to physician- or ACP (respiratory therapist)-led management is reported. Clinical outcomes included adherence to positive airway pressure therapy and patient-reported outcomes including sleepiness, quality of life, and care satisfaction. A cost-utility analysis was conducted using trial data and health administrative data, with costs calculated from the perspective of the Canadian public payer and quality-adjusted life years (QALYs) using Health Utility Index scores. Willingness to pay for incremental cost-effectiveness ratio estimates were summarized with cost-effectiveness acceptability curves. Referral wait times and polysomnogram use were evaluated in subgroup analyses. Adherence, treatment efficacy, and patient-reported outcomes were similar among ACP-led and standard care arms. Mean utility scores improved over the 1-year period in both groups. The estimated incremental cost-effectiveness ratio associated with the ACP-led group compared with standard care was -$34,580 per QALY. The probability the ACP-led clinic was cost-effective compared with standard care was 61.9% at a willingness to pay threshold of $50,000/QALY. Subgroup and sensitivity analyses did not alter results. Our results show that the ACP-led management strategy demonstrated similar clinical outcomes 1 year after treatment initiation. This model is likely to be cost-effective relative to standard care among patients with severe SDB. Results were robust to sensitivity analysis and support implementation of the ACP care model in this population.